Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension

Related Articles
Mayo Clinic AI algorithm proves effective at spotting early-stage heart disease in routine EKG data
FIERCE Biotech: An algorithm developed by the Mayo Clinic can significantly increase the number of cases of low ejection fraction caught in its earliest stages, when it’s still most treatable,…{post_date: F d, Y}
Anumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac Diseases
Anumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac Diseases CAMBRIDGE, Mass. – June 25, 2024 – Anumana, a leading AI-driven health…{post_date: F d, Y}
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
DAIC: Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the…{post_date: F d, Y}
AI researchers at Mayo Clinic use the Apple Watch to detect silent, weakening heart disease
FIERCE Biotech: Using simplified ECG data taken from an Apple Watch, researchers at the Mayo Clinic were able to use an artificial intelligence algorithm to spot people whose hearts may…{post_date: F d, Y}


